Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KT032 in Mesothelin-positive Advanced Solid Tumors
NCT07420010Phase 1Not yet recruiting
- Start
- Mar 2026
- Primary completion
- Dec 2028
- Modality
- CAR-T Cells
01
Overview
Phase 1, open-label trial of KT032 in solid tumor, ovarian cancer, mesothelioma and 1 more (3 arms). Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximal Tolerable Dose at 28 days and 3 more. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
KT032
03
Conditions
solid tumorovarian cancermesotheliomacolon cancer
Beyond the preview
Go deeper on NCT07420010.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07420010.